Table 2. Clinicopathological characteristics of each RTKs overexpression.
| Characteristics | HER2 | EGFR | MET | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive* | Negative | P | Positive | Negative | P | Positive | Negative | P | ||||||||
| 3+ | 2+ | 1+ | 0 | 3+ | 2+ | 1+ | 0 | 3+ | 2+ | 1+ | 0 | |||||
| Total (%) | 438 | 46 (10.5) | 13 (3.0) | 92 (21.0) | 287 (65.5) | − | 54 (12.3) | 121 (27.6) | 232 (53.0) | 31 (7.1) | 20 (4.6) | 33 (7.5) | 284 (64.8) | 101 (23.1) | − | |
| Age, years | ||||||||||||||||
| Median | 57 | 60 | 56 | 0.04 | 58 | 56 | 0.21 | 58 | 56 | 0.26 | ||||||
| Range | 22-86 | 22-82 | 23-86 | 22-86 | 23-85 | 29-86 | 22-86 | |||||||||
| Sex | ||||||||||||||||
| Male | 300 | 44 (50.8%) | 256 (67.5%) | 0.28 | 129 (73.7%) | 171 (65.0%) | 0.04 | 31 (58.5%) | 269 (69.9%) | 0.1 | ||||||
| Female | 138 | 15 (49.2%) | 123 (32.5%) | 46 (26.3%) | 92 (35.0%) | 22 (41.5%) | 116 (30.1%) | |||||||||
| Metastatic site | ||||||||||||||||
| Liver | 73 | 18 (24.7%) | 55 (75.3%) | <0.001 | 30 (41.1%) | 43 (58.9%) | 0.83 | 10 (13.7%) | 63 (86.3%) | 0.65 | ||||||
| Lymph node | 72 | 15 (20.8%) | 57 (79.2%) | 0.04 | 35 (48.6%) | 37 (51.4%) | 0.10 | 16 (22.2%) | 56 (77.8%) | <0.001 | ||||||
| Peritoneum | 140 | 13 (9.3%) | 127 (33.5%) | 0.08 | 51 (36.4%) | 89 (63.6%) | 0.30 | 13 (9.3%) | 127 (90.7%) | 0.22 | ||||||
| Bone | 21 | 3 (14.3%) | 18 (85.7%) | 0.91 | 8 (38.1%) | 13 (61.9%) | 0.86 | 3 (14.3%) | 18 (85.7%) | 0.75 | ||||||
| Lung | 13 | 5 (38.5%) | 8 (61.5%) | 0.01 | 9 (69.2%) | 4 (30.8%) | 0.03 | 2 (15.4%) | 11 (84.6%) | 0.71 | ||||||
| Brain | 2 | 0 | 2 (100%) | 0.57 | 2 (100%) | 0 | 0.08 | 0 | 2 (100%) | 0.59 | ||||||
| Others | 58 | 9 (15.5%) | 49 (84.5%) | 0.62 | 21 (36.2%) | 37 (63.8%) | 0.53 | 4 (6.9%) | 54 (93.1%) | 0.19 | ||||||
| Location | ||||||||||||||||
| Upper/middle | 285 | 30 (50.8%) | 255 (67.3%) | 0.01 | 106 (60.6%) | 179 (68.1%) | 0.10 | 32 (60.4%) | 253 (65.7%) | 0.45 | ||||||
| Lower | 153 | 29 (49.2%) | 124 (32.7%) | 69 (39.4%) | 84 (31.9%) | 21 (39.6%) | 132 (34.3%) | |||||||||
| Histology† | ||||||||||||||||
| Diff | 149 | 35 (59.3%) | 114 (30.1%) | <0.001 | 71 (40.6%) | 78 (29.7%) | 0.02 | 19 (35.8%) | 130 (33.8%) | 0.76 | ||||||
| Undiff | 289 | 24 (40.7%) | 265 (69.9%) | 104 (59.4%) | 185 (70.3%) | 34 (64.2%) | 255 (66.2%) | |||||||||
| Lauren classification (n=245) | ||||||||||||||||
| Intestinal | 98 | 18 (62.1%) | 80 (37.0%) | 0.03 | 51 (53.1%) | 47 (31.5%) | <0.001 | 10 (47.6%) | 88 (39.3%) | 0.73 | ||||||
| Diffuse | 130 | 10 (34.5%) | 120 (55.6%) | 39 (40.6%) | 91 (61.1%) | 10 (47.6%) | 120 (53.6%) | |||||||||
| Mixed | 17 | 1 (3.4%) | 16 (7.4%) | 6 (6.3%) | 11 (7.4%) | 1 (4.8%) | 16 (7.1%) | |||||||||
| Borrmann (n=406) | ||||||||||||||||
| 1 | 17 | 2 (3.5%) | 15 (4.3%) | 0.84 | 6 (3.6%) | 11 (4.6%) | 0.1 | 2 (4.3%) | 15 (4.2%) | 0.28 | ||||||
| 2 | 71 | 10 (17.5%) | 61 (17.5%) | 31 (18.6%) | 40 (16.7%) | 12 (25.5%) | 59 (16.4%) | |||||||||
| 3 | 223 | 34 (59.6%) | 189 (54.2%) | 101 (60.5%) | 122 (51.0%) | 20 (42.6%) | 203 (56.5%) | |||||||||
| 4 | 95 | 11 (19.3%) | 84 (24.1%) | 29 (17.4%) | 66 (27.6%) | 13 (27.7%) | 82 (22.8%) | |||||||||
| Stage | ||||||||||||||||
| I | 23 | 0 | 23 (6.1%) | 0.02 | 10 (5.7%) | 13 (4.9%) | 0.95 | 4 (7.5%) | 19 (4.9%) | 0.02 | ||||||
| II | 87 | 6 (10.2%) | 81 (21.4%) | 34 (19.4%) | 53 (20.2%) | 4 (7.5%) | 83 (21.6%) | |||||||||
| III | 130 | 18 (30.5%) | 112 (29.6%) | 50 (28.6%) | 80 (30.4%) | 12 (22.6%) | 118 (30.6%) | |||||||||
| IV | 198 | 35 (59.3%) | 163 (43.0%) | 81 (46.3%) | 117 (44.5%) | 33 (62.3%) | 165 (42.9%) | |||||||||
*
All IHC score of 3+ or a score of 2+ plus HER2 gene amplification was defined as HER2 3+.
†
Histology: diff; differentiated, undiff; undifferentiated